Britain and America have forged a major bilateral deal that will keep zero tariffs on British drug products going into the American market.
The Terms of the Deal
As part of the deal, the UK has committed to raise spending on drugs through the NHS. This pledge guarantees that duties on these key exports will stay at zero for a timeframe of the next three years.
This development is in response to earlier warnings to significantly raise duties on patented drug products, with increases mentioned as high as double the cost.
"This arrangement with the UK bolsters the global environment for innovative medicines and introduces long-overdue equity to transatlantic medicine commerce," a statement declared.
Commercial Impact
Medicines constitute one of the UK's most significant export categories to the America, which is clearly the biggest buyer for leading UK drugmakers.
Export figures show that in the 12 months prior to last September, the UK sold medicines totaling billions to the US. This amount made up a significant portion of British export trade in that period.
"This agreement safeguards employment, increases funding and facilitates the UK to emerge as a international leader for medical research," a government official commented.
Key NHS Changes
The agreement entails several notable commitments from the UK:
- Revised Affordability Limit: The UK will lift the price threshold at which it deems new medicines to be unaffordable by 25%.
- Increased NHS Spending: There is a target to increase overall health service expenditure on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be capped at 15%. Previously, refunds were more than 20%.
Recent Tensions
This agreement takes place against a ongoing tension between the sector and the ministers over medicine costs and regulatory access.
This friction were exacerbated by claims that American patients were charged a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been paused or scrapped, while major investments have been announced toward US facilities.
One official acknowledged that the NHS had to spend more on drugs, noting that its spending on drugs had declined as a share of its total funding over the last ten years.
